University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Strong Futures: A Trial of Two Primary Care Based Interventions to Promote Optimal Health in Latino Infants and Toddlers

Not Applicable

Completed

Conditions: Health-Related Quality of Life
Childhood Obesity

Interventions: Behavioral: Infant obesity prevention
Behavioral: Financial coaching

First Posted Date: 2018-02-20

Last Posted Date: 2021-11-16

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 194

Registration Number: NCT03438721

Locations: 🇺🇸
Children's Health Center at San Francisco General Hospital, San Francisco, California, United States

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Phase 2

Active, not recruiting

Conditions: Stage IIA Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer
Stage I Non-Small Cell Lung Cancer
Stage IB Non-Small Cell Lung Cancer
Stage IA Non-Small Cell Lung Cancer
Stage II Non-Small Cell Lung Cancer
Stage IIB Non-Small Cell Lung Cancer

Interventions: Drug: Osimertinib
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2018-02-14

Last Posted Date: 2024-01-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 27

Registration Number: NCT03433469

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
University of California, Davis, Davis, California, United States

Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

Phase 1

Withdrawn

Conditions: Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7
Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7

Interventions: Other: Laboratory Biomarker Analysis
Biological: Talimogene Laherparepvec

First Posted Date: 2018-02-13

Last Posted Date: 2020-07-28

Lead Sponsor: University of California, San Francisco

Registration Number: NCT03430687

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Ultra Dual-Energy X-ray Absorptiometry (DXA): Accurate and Precise Quantitative Multi-compartment Body Composition

Completed

Conditions: Body Composition

First Posted Date: 2018-02-12

Last Posted Date: 2019-03-07

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 33

Registration Number: NCT03430323

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Improving Preterm Infant Outcomes With Family Integrated Care and Mobile Technology

Not Applicable

Completed

Conditions: Premature Birth of Newborn

Interventions: Behavioral: Family Integrated Care

First Posted Date: 2018-02-01

Last Posted Date: 2021-03-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 347

Registration Number: NCT03418870

Locations: 🇺🇸
Community Regional Medical Center, Fresno, California, United States
🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸
UCSF Benioff Children's Hospital San Francisco, San Francisco, California, United States

and more 3 locations

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

Phase 2

Withdrawn

Conditions: Infiltrating Bladder Urothelial Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7

Interventions: Radiation: Hypofractionated Radiation Therapy
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Radiation: Radiation Therapy

First Posted Date: 2018-02-01

Last Posted Date: 2018-12-07

Lead Sponsor: University of California, San Francisco

Registration Number: NCT03419130

Locations: 🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States

Hydrops: Diagnosing & Redefining Outcomes With Precision Study

Not Applicable

Conditions: Hydrops Fetalis
Fetal Anomaly
Birth Defect

Interventions: Diagnostic Test: Exome sequencing

First Posted Date: 2018-01-26

Last Posted Date: 2024-02-01

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 500

Registration Number: NCT03412760

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease

Not Applicable

Completed

Conditions: Alzheimer Disease

Interventions: Other: Sham Vielight Neuro Gamma
Device: Vielight Neuro Gamma

First Posted Date: 2018-01-23

Last Posted Date: 2022-07-01

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 23

Registration Number: NCT03405662

Locations: 🇺🇸
VA Health Care System, San Francisco, California, United States
🇺🇸
UCSF Memory and Aging Center, San Francisco, California, United States

Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Stage IIIB Colorectal Cancer AJCC v7
Stage IIIC Colorectal Cancer AJCC v7
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Microsatellite Stable
Stage III Colorectal Cancer AJCC v7
Mismatch Repair Protein Proficient
Stage IVB Colorectal Cancer AJCC v7

Interventions: Biological: Bevacizumab
Drug: Capecitabine
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2018-01-11

Last Posted Date: 2024-03-07

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 44

Registration Number: NCT03396926

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Pioneering Advances in Care and Education (PACE)

Not Applicable

Completed

Conditions: Decision Support Systems, Clinical
Prostate Cancer

Interventions: Behavioral: Decision Support Intervention (DSI)

First Posted Date: 2018-01-11

Last Posted Date: 2023-06-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 119

Registration Number: NCT03397160

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
CentraCare Clinic Adult & Pediatric Urology, Sartell, Minnesota, United States
🇺🇸
Palo Alto Medical Foundation, Palo Alto, California, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy